Annual Report

Overview

The report describes 2025 progress in the company's oncology and non-oncology pipelines, including late-stage osemitamab development and ongoing early-stage programs. It records a strategic collaboration and non-exclusive licensing agreement with EirGenix to advance integrated continuous biomanufacturing. The company also completed a share placement raising approximately HK$59.34 million net. Financially, revenue fell to RMB7.4 million and the report discusses liquidity pressure and going-concern mitigation measures.

Document

Report type: Annual Report
Class: Financial
Scope: Full report
Fiscal year: 2025
Period: Ends 31 December 2025
Publication date: 30 March 2026
Language: English
Pages
File size

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services